NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Forecast & News

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) released its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.18. The biotechnology company had revenue of $15.13 million for the quarter, compared to the consensus estimate of $6.28 million. Pieris Pharmaceuticals had a negative net margin of 107.24% and a negative return on equity of 132.02%. View Pieris Pharmaceuticals' Earnings History.

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Pieris Pharmaceuticals.

4 brokers have issued 1-year price targets for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Pieris Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 77.2% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.

News articles about PIRS stock have trended positive recently, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pieris Pharmaceuticals earned a news impact score of 2.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near future. View News Stories for Pieris Pharmaceuticals.

Pieris Pharmaceuticals saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,180,000 shares, a decline of 32.6% from the January 15th total of 1,750,000 shares. Based on an average trading volume of 564,500 shares, the days-to-cover ratio is currently 2.1 days. Approximately 2.4% of the company's shares are sold short. View Pieris Pharmaceuticals' Current Options Chain.

Some companies that are related to Pieris Pharmaceuticals include Intrexon (XON), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), STARPHARMA HOLD/S (SPHRY), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), US Stem Cell (USRM), Vitality Biopharma (VBIO) and Protalex (PRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), Omeros (OMER), Agile Therapeutics (AGRX), Exelixis (EXEL), Marinus Pharmaceuticals (MRNS), Sangamo Therapeutics (SGMO) and Amarin (AMRN).

Pieris Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (4.61%), Renaissance Technologies LLC (3.61%), Candriam Luxembourg S.C.A. (2.71%), State Street Corp (1.79%), Samsara BioCapital LLC (1.28%) and Geode Capital Management LLC (1.14%). Company insiders that own Pieris Pharmaceuticals stock include Bvf Partners L P/Il, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

PIRS stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Spark Investment Management LLC, Alpine Global Management LLC, Meeder Asset Management Inc. and Algert Global LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

PIRS stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Candriam Luxembourg S.C.A., Samsara BioCapital LLC, Parkman Healthcare Partners LLC, Marshall Wace North America L.P., Voss Capital LLC, Jacobs Levy Equity Management Inc. and Panagora Asset Management Inc.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $3.95.

Pieris Pharmaceuticals has a market capitalization of $217.17 million and generates $29.10 million in revenue each year. The biotechnology company earns $-26,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.View Additional Information About Pieris Pharmaceuticals.

The official website for Pieris Pharmaceuticals is http://www.pieris.com/.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]